© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
Movement Disorders
Indu Subramanian, MD: Social Prescribing for Patients With Parkinson Disease
September 18, 2020
Video
The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers explained how social prescribing can play a key role in the prevention of social isolation.
Stewart Factor, MD: Long-Term Data on Apomorphine Sublingual Film in Parkinson
September 17, 2020
Video
The director of the Movement Disorders Program and Vance Lanier Chair of Neurology at Emory University School of Medicine gave his perspective on the interim findings of a long-term safety study of apomorphine sublingual film.
Addressing Loneliness and Social Isolation in Patients With Parkinson Disease
September 17, 2020
Article
The director of the VA Southwest Parkinson’s Disease Research, Education, and Clinical Centers offered background the inspiration for the study and why loneliness should be addressed in these patients.
Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD
September 17, 2020
Article
Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.
Joaquim Ferreria, MD, PhD: Opicapone’s Use in Levodopa-Treated Patients With Parkinson Disease
September 16, 2020
Video
The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.
Apomorphine Sublingual Film Shows Long-Term Efficacy in OFF Episode Treatment
September 16, 2020
Article
The recently approved apomorphine sublingual film (Kynmobi; Sunovion) maintained efficacy over the long-term, with at least 74% of patients experiencing full ON within 30 minutes post-dose at each time point.